| Title | The role of exogenous surfactant in the treatment of preterm neonates with chronic lung disease | |
| Authors | Christos Tsakalidis, Paraskevi Karagianni, Dimitris Rallis, Evangelia Giougki, Anastasia Kalesi, Charalampos Dokos and Nikolaos Nikolaidis
2nd Neonatal Intensive Care Unit, General Hospital Papageorgiou, Aristotle University, Thessaloniki, Hellas |
|
| Citation | Tsakalidis, C., Karagianni, P., Rallis, D., Giougki, E., Kalesi, A. et al.: The role of exogenous surfactant in the treatment of preterm neonates with chronic lung disease, Epitheorese Klin. Farmakol. Farmakokinet. 24(3): 247-253 (2010) | |
| Publication Date | Accepted for publication (Final Version): April 10, 2010 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Oxygenation index, alveolar-arterial oxygen difference, arterial-alveolar oxygen ratio, surfactant, chronic lung disease. | |
| Other Terms | review article | |
| Summary | The aim of this study was to investigate the effect of surfactant (SF) administration in the treatment of respiratory insufficiency in neonates with Chronic Lung Disease (CLD). 32 premature neonates with birth weight (BW) <1500gr, who at the age of 8-30 days needed mechanical ventilation with FiO2 at least 0.4 along with radiological findings compatible with CLD, were prospectively studied. The neonates were randomly classified into two treatment groups: the SFgroup (n=15) that was treated with SF (2 doses of 100mg/Kg of natural bovine surfactant Survanta®) and the control group (n=17). The course of oxygenation index (OI), alveolar-arterial oxygen difference (A-aDO2) and the arterial-alveolar oxygen ratio (Pa/AO2), the duration of mechanical ventilation, oxygen administration, hospitalization and survival were evaluated. The two groups were comparable regarding the epidemiological and clinical characteristics nor did they differ significantly with respect to the frequency of neonatal problems, which affect the appearance of CLD, such as the severity of respiratory distress syndrome (RDS), the frequency of administration and the number of doses of SF for the treatment of RDS, the frequency of patent ductus arteriosis (PDA), the pneumothorax and the sepsis. Surfactant administration not only did it not have any direct good result on the oxygenation estimation indexes but was followed by a transient deterioration of oxygenation and an increase of the need for mechanical ventilation, which returned to the pre-treatment levels in about 6 hours. As far as the remaining indexes survival was high in both groups, while the duration of hospitalization and oxygenation administration was similar. However, the duration of mechanical ventilation was significantly less in the surfactant treated group. Surfactant administration to neonates with CLD contributes to the faster weaning of the neonate from the ventilation, although no immediate improvement in the oxygenation is observed. | |
| References | 1. Northway W.H.,Jr, Rosan R.C., Porter D.Y.: Pulmonary disease following respiratory therapy for hyaline membrane disease: bronchopulmonary dysplasia. N. Engl. J. Med. 276: 357 (1967)
2. Bancalari E., Abdenour G.E., Feller R., Gannon J.: Bronchopulmonary dysplasia. J. Pediatr. 95: 819-23 (1979) 3. Shennan A.T., Dunn M.S., Ohlsson A., Lennox K., Hoskins E.M.: Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirements in the neonatal period. Pediatrics 82: 527 (1988) 4. Bancalari E., Claure N., Sosenko I.R.: Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin. Neonatol. 8: 63-71 (2003) 5. Lemons J.A., Bauer C.R., Oh W., Korones S.B., Papile C.A., Stoll B.J., et al.: Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 107: 1-8 (2001) 6. Collaborative European Multicenter Study Group: Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82: 683-690 (1990) 7. Schwarz R.M., Luby A.M., Scanlon J.W., Kellogg R.J.: Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N. Engl. J. Med. 330: 1476-1480 (1994) 8. Taghizadeh A., Reuynolds E.D.: Pathogenesis of bronchopulmonary dysplasia following hyaline membrane disease. Am. J. Pathol. 82: 241-264 (1976) 9. Palta M., Gabbert D., Weinstein M.R., Peters M.E.: Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. J. Pediatr. 119: 285-292 (1991) 10. Jobe A.H., Bancalari E.: Bronchopulmonary dysplasia. NICHD – NHLBI – ORD Workshop. An. J. Respir. Crit. Care Med. 163: 1823-1829 (2001) 11. Gerdes J.S., Yoder M.C., Douglas S.D., Paul M., Harris M.C., Polin R.A.: Tracheal lavage and plasma fibronectin: relationship to respiratory distress syndrome and development of bronchopulmonary dysplasia. J. Pediatr. 108: 601-606 (1986) 12. Groneck P., Gotze-Speer B., Oppermann M.. Eiffert H., Speer C.P.: Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonate. Pediatrics 93: 712-718 (1994) 13. Hannaford K., Todd D.A., Jeffery H., John E., Blyth K., Gilbert C.L.: Role of Ureaplasma urealyticum in lung disease of prematurity. Arch. Dis. Child. Fetal. Neonatal. Ed. 81: F162-167 (1999) 14. Pierce M.R., Bancalari E.: The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr. Pulmonol. 19: 371-378 (1995) 15. Watterberg K.L., Carmichael D.F., Gerdes J.S., Werner S., Backstrom C., Murphy S.: Secretoryleukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J. Pediatr. 125: 264-269b (1994) 16. Watterberg K.L., Demers L.M., Scott S.M., Murphy S.: Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97: 210-215 (1996) 17. Speer C.P.: Inflammation and bronchopulmonary dysplasia. Semin. Neonatol. 8: 29-38 (2003) 18. Tammela O.K., Koivisto M.E.: Fluid restriction for prevention bronchopulmonary dysplasia? Reduced fluid intake during the firsts weeks of life improves the outcome of low – birth weight infants. Acta Paediatr. 81: 207-212 (1992) 19. Van Marter L.J., Leviton A., Allred E.N., Pagano M., Kuban K.C.: Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. J. Pediatr. 116: 942-949 (1990) 20. Sosenko I.R.S., Kinter M.T., Roberts R.J.: Nutritional issues in chronic lung disease of premature infants. In: (Bland R.J., Coalson J.J., eds) Chronic Lung Disease in early Infancy. Pp. 285-296, Marcel Dekker, New York, 2000 21. Tyson J.E., Wright L.L.E., Oh W., Kennedy K.A., Mele L., Ehrenkranz R.A., et al.: Vitamin A supplementation for extremely-low-birth-weight infants. N. Engl. J. Med. 340: 1962-1268 (1999) 22. Hallman M.: Genetic influences and neonatal lung disease. Semin. Neonatol. 8: 19-27 (2003) 23. Gerhardt T., Hehre D., Feller R., Reifenberg L., Bancalari E.: Serial determination of pulmonary function in infants with chronic lung disease. J. Pediatr. 110: 448 (1987) 24. Greenspan J.S., DeGiulio P.A., Bhutaniv K.: Airway reactivity as determined by a cold air challenge in infants with bronchopulmonary dysplasia. J. Pediatr. 114: 452-454 (1989) 25. Watterberg K.L., Scott S.M.: Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 95: 120-125 (1995) 26. Watterberg K.L., Gerdes J.S., Gifford K.L., Lin H.M.: Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 104: 1258-1263 (1999) 27. Watterberg K.L., Scott S.M., Backstrom C., Gifford K.L., Cook K.L.: Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 15: 320-324 (2000) 28. Ballard R.A., Nogee L.M., Beers M.F., Ballard P.L., Plane B.C., Polk E.L., et al.: Partial deficiency of surfactant protein B in an infant with chronic lung disease. Pediatrics 96: 1046-1052 (1995) 29. Jackson J.C., Palmer S., Truog W.E., Standaert T.A., Murphy J.H., Hodson W.A.: Surfactant quantity and composition during recovery from hyaline membrane disease. Pediatr. Res. 20: 1243-1247 (1986) 30. LaGagnin L.B., Bowman L., Ma J.Y.C., Miles P.R.: Metabolic changes in alveolar type II cells after exposure to hydrogen peroxide. Am. J. Physiol. 259: L57-L65 (1990) 31. Batenburg J.J., Hallman M.: Developmental biochemistry of alveoli. In: (Scaerpelli E.M., ed.) Pulmonary Physiology: Fetus-newborn-child-adolescent. 2nd ed., pp. 106-139, Lea & Febiger, Piladelphia, 1990 32. Hallman M., Merritt T.A., Akino T., Bry K.: Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am. Rev. Respir. Dis. 144: 1376-1384 (1991) 33. Obladen M.: Factors influencing surfactant composition in the newborn infant. Eur. J. Pediatr. 128: 129-143 (1978) 34. Tsakalidis C., Giougi E., Kalesi A., Dokos C.: Surfactant in premature infants with Chronic Lung Disease. Rev. Clin. Pharmacol. Pharmacokinet. 24: 49-53 (2010) 35. Pandit P.B., Dunn M.S., Kelly E.N., Perlman M.: Surfactant replacement in neonates with early chronic lung disease. Pediatrics 95: 851-854 (1995) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2010 – ANNUAL SUBSCRIPTION 2010 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|